Response to valganciclovir in chronic fatigue syndrome patients with human herpesvirus 6 and Epstein-Barr virus IgG antibody titers

Tessa Watt, Stephanie Oberfoell, Raymond Balise, Mitchell R. Lunn, Aroop K. Kar, Lindsey Merrihew, Munveer S. Bhangoo, José G. Montoya

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Valganciclovir has been reported to improve physical and cognitive symptoms in patients with chronic fatigue syndrome (CFS) with elevated human herpesvirus 6 (HHV-6) and Epstein-Barr virus (EBV) IgG antibody titers. This study investigated whether antibody titers against HHV-6 and EBV were associated with clinical response to valganciclovir in a subset of CFS patients. An uncontrolled, unblinded retrospective chart review was performed on 61 CFS patients treated with 900mg valganciclovir daily (55 of whom took an induction dose of 1,800mg daily for the first 3 weeks). Antibody titers were considered high if HHV-6 IgG ≥1:320, EBV viral capsid antigen (VCA) IgG ≥1:640, and EBV early antigen (EA) IgG ≥1:160. Patients self-rated physical and cognitive functioning as a percentage of their functioning prior to illness. Patients were categorized as responders if they experienced at least 30% improvement in physical and/or cognitive functioning. Thirty-two patients (52%) were categorized as responders. Among these, 19 patients (59%) responded physically and 26 patients (81%) responded cognitively. Baseline antibody titers showed no significant association with response. After treatment, the average change in physical and cognitive functioning levels for all patients was +19% and +23%, respectively (P<0.0001). Longer treatment was associated with improved response (P=0.0002). No significant difference was found between responders and non-responders among other variables analyzed. Valganciclovir treatment, independent of the baseline antibody titers, was associated with self-rated improvement in physical and cognitive functioning for CFS patients who had positive HHV-6 and/or EBV serologies. Longer valganciclovir treatment correlated with an improved response.

Original languageEnglish (US)
Pages (from-to)1967-1974
Number of pages8
JournalJournal of Medical Virology
Volume84
Issue number12
DOIs
StatePublished - Dec 2012
Externally publishedYes

Fingerprint

Human Herpesvirus 6
Chronic Fatigue Syndrome
Human Herpesvirus 4
Immunoglobulin G
Antibodies
valganciclovir
Neurobehavioral Manifestations
Serology
Therapeutics

Keywords

  • CFS
  • EBV
  • HHV-6

ASJC Scopus subject areas

  • Virology
  • Infectious Diseases

Cite this

Response to valganciclovir in chronic fatigue syndrome patients with human herpesvirus 6 and Epstein-Barr virus IgG antibody titers. / Watt, Tessa; Oberfoell, Stephanie; Balise, Raymond; Lunn, Mitchell R.; Kar, Aroop K.; Merrihew, Lindsey; Bhangoo, Munveer S.; Montoya, José G.

In: Journal of Medical Virology, Vol. 84, No. 12, 12.2012, p. 1967-1974.

Research output: Contribution to journalArticle

Watt, Tessa ; Oberfoell, Stephanie ; Balise, Raymond ; Lunn, Mitchell R. ; Kar, Aroop K. ; Merrihew, Lindsey ; Bhangoo, Munveer S. ; Montoya, José G. / Response to valganciclovir in chronic fatigue syndrome patients with human herpesvirus 6 and Epstein-Barr virus IgG antibody titers. In: Journal of Medical Virology. 2012 ; Vol. 84, No. 12. pp. 1967-1974.
@article{942a5234535f4615b4e35f9db17c9682,
title = "Response to valganciclovir in chronic fatigue syndrome patients with human herpesvirus 6 and Epstein-Barr virus IgG antibody titers",
abstract = "Valganciclovir has been reported to improve physical and cognitive symptoms in patients with chronic fatigue syndrome (CFS) with elevated human herpesvirus 6 (HHV-6) and Epstein-Barr virus (EBV) IgG antibody titers. This study investigated whether antibody titers against HHV-6 and EBV were associated with clinical response to valganciclovir in a subset of CFS patients. An uncontrolled, unblinded retrospective chart review was performed on 61 CFS patients treated with 900mg valganciclovir daily (55 of whom took an induction dose of 1,800mg daily for the first 3 weeks). Antibody titers were considered high if HHV-6 IgG ≥1:320, EBV viral capsid antigen (VCA) IgG ≥1:640, and EBV early antigen (EA) IgG ≥1:160. Patients self-rated physical and cognitive functioning as a percentage of their functioning prior to illness. Patients were categorized as responders if they experienced at least 30{\%} improvement in physical and/or cognitive functioning. Thirty-two patients (52{\%}) were categorized as responders. Among these, 19 patients (59{\%}) responded physically and 26 patients (81{\%}) responded cognitively. Baseline antibody titers showed no significant association with response. After treatment, the average change in physical and cognitive functioning levels for all patients was +19{\%} and +23{\%}, respectively (P<0.0001). Longer treatment was associated with improved response (P=0.0002). No significant difference was found between responders and non-responders among other variables analyzed. Valganciclovir treatment, independent of the baseline antibody titers, was associated with self-rated improvement in physical and cognitive functioning for CFS patients who had positive HHV-6 and/or EBV serologies. Longer valganciclovir treatment correlated with an improved response.",
keywords = "CFS, EBV, HHV-6",
author = "Tessa Watt and Stephanie Oberfoell and Raymond Balise and Lunn, {Mitchell R.} and Kar, {Aroop K.} and Lindsey Merrihew and Bhangoo, {Munveer S.} and Montoya, {Jos{\'e} G.}",
year = "2012",
month = "12",
doi = "10.1002/jmv.23411",
language = "English (US)",
volume = "84",
pages = "1967--1974",
journal = "Journal of Medical Virology",
issn = "0146-6615",
publisher = "Wiley-Liss Inc.",
number = "12",

}

TY - JOUR

T1 - Response to valganciclovir in chronic fatigue syndrome patients with human herpesvirus 6 and Epstein-Barr virus IgG antibody titers

AU - Watt, Tessa

AU - Oberfoell, Stephanie

AU - Balise, Raymond

AU - Lunn, Mitchell R.

AU - Kar, Aroop K.

AU - Merrihew, Lindsey

AU - Bhangoo, Munveer S.

AU - Montoya, José G.

PY - 2012/12

Y1 - 2012/12

N2 - Valganciclovir has been reported to improve physical and cognitive symptoms in patients with chronic fatigue syndrome (CFS) with elevated human herpesvirus 6 (HHV-6) and Epstein-Barr virus (EBV) IgG antibody titers. This study investigated whether antibody titers against HHV-6 and EBV were associated with clinical response to valganciclovir in a subset of CFS patients. An uncontrolled, unblinded retrospective chart review was performed on 61 CFS patients treated with 900mg valganciclovir daily (55 of whom took an induction dose of 1,800mg daily for the first 3 weeks). Antibody titers were considered high if HHV-6 IgG ≥1:320, EBV viral capsid antigen (VCA) IgG ≥1:640, and EBV early antigen (EA) IgG ≥1:160. Patients self-rated physical and cognitive functioning as a percentage of their functioning prior to illness. Patients were categorized as responders if they experienced at least 30% improvement in physical and/or cognitive functioning. Thirty-two patients (52%) were categorized as responders. Among these, 19 patients (59%) responded physically and 26 patients (81%) responded cognitively. Baseline antibody titers showed no significant association with response. After treatment, the average change in physical and cognitive functioning levels for all patients was +19% and +23%, respectively (P<0.0001). Longer treatment was associated with improved response (P=0.0002). No significant difference was found between responders and non-responders among other variables analyzed. Valganciclovir treatment, independent of the baseline antibody titers, was associated with self-rated improvement in physical and cognitive functioning for CFS patients who had positive HHV-6 and/or EBV serologies. Longer valganciclovir treatment correlated with an improved response.

AB - Valganciclovir has been reported to improve physical and cognitive symptoms in patients with chronic fatigue syndrome (CFS) with elevated human herpesvirus 6 (HHV-6) and Epstein-Barr virus (EBV) IgG antibody titers. This study investigated whether antibody titers against HHV-6 and EBV were associated with clinical response to valganciclovir in a subset of CFS patients. An uncontrolled, unblinded retrospective chart review was performed on 61 CFS patients treated with 900mg valganciclovir daily (55 of whom took an induction dose of 1,800mg daily for the first 3 weeks). Antibody titers were considered high if HHV-6 IgG ≥1:320, EBV viral capsid antigen (VCA) IgG ≥1:640, and EBV early antigen (EA) IgG ≥1:160. Patients self-rated physical and cognitive functioning as a percentage of their functioning prior to illness. Patients were categorized as responders if they experienced at least 30% improvement in physical and/or cognitive functioning. Thirty-two patients (52%) were categorized as responders. Among these, 19 patients (59%) responded physically and 26 patients (81%) responded cognitively. Baseline antibody titers showed no significant association with response. After treatment, the average change in physical and cognitive functioning levels for all patients was +19% and +23%, respectively (P<0.0001). Longer treatment was associated with improved response (P=0.0002). No significant difference was found between responders and non-responders among other variables analyzed. Valganciclovir treatment, independent of the baseline antibody titers, was associated with self-rated improvement in physical and cognitive functioning for CFS patients who had positive HHV-6 and/or EBV serologies. Longer valganciclovir treatment correlated with an improved response.

KW - CFS

KW - EBV

KW - HHV-6

UR - http://www.scopus.com/inward/record.url?scp=84867708922&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867708922&partnerID=8YFLogxK

U2 - 10.1002/jmv.23411

DO - 10.1002/jmv.23411

M3 - Article

C2 - 23080504

AN - SCOPUS:84867708922

VL - 84

SP - 1967

EP - 1974

JO - Journal of Medical Virology

JF - Journal of Medical Virology

SN - 0146-6615

IS - 12

ER -